Langerhans Cell Histiocytosis Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Langerhans Cell Histiocytosis Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version

Go to Patient Version

LANGERHANS CELL HISTIOCYTOSIS

• Patient
• Health Professional
  • Langerhans Cell Histiocytosis Treatment

SECTIONS

• General Information About Langerhans Cell Histiocytosis (LCH)
• Histopathologic, Immunologic, and Cytogenetic Characteristics of LCH
• Childhood LCH
• Treatment of Childhood LCH
• Treatment of Recurrent, Refractory, or Progressive Childhood LCH
• Late Disease and Treatment Effects of Childhood LCH
• Adult LCH
• Treatment of Adult LCH
• Changes to This Summary (11/​09/​2017)
• About This PDQ Summary
• View All Sections

Changes to This Summary (11/09/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was comprehensively reviewed and extensively revised.

This summary was reformatted.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.